 RedHill Biopharma NASDAQ: RDHL has announced that all treatment and follow-up has now been completed in the 475-patient global Phase 23 study with opaganib ABC294640 in patients hospitalized with severe COVID-19 pneumonia NCT04467840, with top-line results expected in the coming weeks. RedHill is a leader in the development of novel oral therapies for COVID-19, with two first-in-class oral candidates in Phase 23 testing. 